标题
Targeted therapy for triple-negative breast cancer: Where are we?
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CANCER
Volume 131, Issue 11, Pages 2471-2477
出版商
Wiley
发表日期
2012-05-14
DOI
10.1002/ijc.27632
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- P3-17-03: ADAM17: A Novel Therapeutic Target for Treatment of Triple Negative Breast Cancer.
- (2012) PM McGowan et al. CANCER RESEARCH
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Src: a potential target for the treatment of triple-negative breast cancer
- (2011) D. Tryfonopoulos et al. ANNALS OF ONCOLOGY
- Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
- (2011) R. S. Finn et al. CLINICAL CANCER RESEARCH
- Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo
- (2011) Rachel Sharpe et al. CLINICAL CANCER RESEARCH
- Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
- (2011) J. C. Montero et al. CLINICAL CANCER RESEARCH
- Dasatinib
- (2011) Paul L. McCormack et al. DRUGS
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells
- (2011) T. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment
- (2011) E. Grande et al. MOLECULAR CANCER THERAPEUTICS
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Subtype and pathway specific responses to anticancer compounds in breast cancer
- (2011) L. M. Heiser et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype
- (2010) Junichi Kurebayashi et al. BMC CANCER
- Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up
- (2010) Lisa Rydén et al. BREAST CANCER RESEARCH AND TREATMENT
- Synthetic Lethality through Combined Notch-Epidermal Growth Factor Receptor Pathway Inhibition in Basal-Like Breast Cancer
- (2010) Y. Dong et al. CANCER RESEARCH
- Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
- (2010) K. Hastak et al. CANCER RESEARCH
- PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) B. McEllin et al. CANCER RESEARCH
- Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells
- (2010) F. Hochgrafe et al. CANCER RESEARCH
- Targeting DNA repair in breast cancer: A clinical and translational update
- (2010) Eitan Amir et al. CANCER TREATMENT REVIEWS
- Use of molecular markers for predicting therapy response in cancer patients
- (2010) Michael J. Duffy et al. CANCER TREATMENT REVIEWS
- C-MET as a new therapeutic target for the development of novel anticancer drugs
- (2010) Israel Cañadas et al. Clinical & Translational Oncology
- High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti-IGF-IR Therapy
- (2010) B. C. Litzenburger et al. CLINICAL CANCER RESEARCH
- Monitoring Drug-Induced H2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells
- (2010) L. H. Wang et al. CLINICAL CANCER RESEARCH
- Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies
- (2010) E. L. Mayer et al. CLINICAL CANCER RESEARCH
- Histone H2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
- (2010) C. E. Redon et al. CLINICAL CANCER RESEARCH
- Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer
- (2010) C. K. Anders et al. CLINICAL CANCER RESEARCH
- Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer
- (2010) C. M. Annunziata et al. CLINICAL CANCER RESEARCH
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- Targeting the HGF/Met signalling pathway in cancer
- (2010) Fabiola Cecchi et al. EUROPEAN JOURNAL OF CANCER
- Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
- (2010) Yvette Drew et al. JNCI-Journal of the National Cancer Institute
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy
- (2010) S. Moulder et al. MOLECULAR CANCER THERAPEUTICS
- miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
- (2010) Patryk Moskwa et al. MOLECULAR CELL
- Nilotinib and dasatinib—new 'magic bullets' for CML?
- (2010) Massimo Breccia Nature Reviews Clinical Oncology
- Making the best of PARP inhibitors in ovarian cancer
- (2010) Susana Banerjee et al. Nature Reviews Clinical Oncology
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
- (2010) N Turner et al. ONCOGENE
- Predicting Response to EGFR Inhibitors in Metastatic Colorectal Cancer: Current Practice and Future Directions
- (2010) V. Shankaran et al. ONCOLOGIST
- Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies
- (2010) I. Astsaturov et al. Science Signaling
- PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
- (2010) K. J. Dedes et al. Science Translational Medicine
- Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
- (2009) B. Corkery et al. ANNALS OF ONCOLOGY
- Dasatinib synergizes with doxorubicin to block growth, migration and invasion of breast cancer cells
- (2009) C S Pichot et al. BRITISH JOURNAL OF CANCER
- Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
- (2009) B. T. Hennessy et al. CANCER RESEARCH
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
- (2009) M. L. Sos et al. CANCER RESEARCH
- Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
- (2009) F. Andre et al. CLINICAL CANCER RESEARCH
- Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
- (2009) E. A. Rakha et al. CLINICAL CANCER RESEARCH
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- (2009) K. P. Hoeflich et al. CLINICAL CANCER RESEARCH
- HER-2 Signaling and Inhibition in Breast Cancer
- (2009) B. Browne et al. CURRENT CANCER DRUG TARGETS
- Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors
- (2009) Ana M. Mendes-Pereira et al. EMBO Molecular Medicine
- PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
- (2009) Fotios Loupakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin
- (2009) P. Ceppi et al. MOLECULAR CANCER THERAPEUTICS
- Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
- (2009) Elgene Lim et al. NATURE MEDICINE
- Src kinases as therapeutic targets for cancer
- (2009) Lori C. Kim et al. Nature Reviews Clinical Oncology
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer
- (2009) C. R. Graveel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer
- (2009) M. G. Ponzo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Developing c-MET pathway inhibitors for cancer therapy: progress and challenges
- (2009) Xiangdong Liu et al. TRENDS IN MOLECULAR MEDICINE
- Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity
- (2008) Giuseppe Viale et al. BREAST CANCER RESEARCH AND TREATMENT
- Drug Resistance Caused by Reversion Mutation
- (2008) A. Ashworth CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now